Table 37 (Abstract P130). Demographic characteristics, seroprotection rates and mean rubella-IgG titers for the SLE and the control group
From: Proceedings of the 24th Paediatric Rheumatology European Society Congress: Part one
Parameters | SLE group | Control group | P value |
|---|---|---|---|
Study sample, n | 21 | 76 | 0.9* |
Age, years, mean (SD) | 13.3 (2.3) | 13 (2.7) | 0.8* |
Gender n (%) | |||
female | 20 (95%) | 72 (95%) | 0.83+ |
male | 1 (5%) | 4 (5%) | |
Steroids (21/21) | Â | Â | - |
- · mean dose | 10 mg | NA |  |
- · mean duration of treatment | 17 months | ||
HCQ (21/21) | |||
- · mean dose | 200 mg |  |  |
- · mean duration of treatment | 36 months | ||
Azathioprine (9/21) | |||
- · mean dose | 75 mg |  |  |
- · mean duration of treatment | 18 months | ||
SLEDAI score | |||
- · Enrolment | 7 |  |  |
- · 1 year | 1 | ||
- · 3 years | 0 | ||
Seroprotection rate at diagnosis (%) | 95 | 98 | 0.4+ |
Seroprotection rate at 1Â year (%) | 92 | 97 | 0.1+ |
Seroprotection rate at 3Â years (%) | 89 | 96 | 0.04+ |
Mean IgG titers at diagnosis, mIU/ml | 432 | 590 | < 0.01* |
Mean IgG titers at 1Â year, mIU/ml | 340 | 554 | < 0.01* |
Mean IgG titers at 3Â years, mIU/ml | 298 | 468 | < 0.01* |